Department of Respiratory Medicine, The Zengcheng Branch of Nanfang Hospital, Southern Medical University, 511300 Guangzhou, Guangdong, China.
Dian Diagnostics Group Co., Ltd., 310000 Hangzhou, Zhejiang, China.
Discov Med. 2023 Jun;35(176):332-342. doi: 10.24976/Discov.Med.202335176.34.
It is common to obtain a low detection rate and unsatisfactory detection results in complex infection or rare pathogen detection. This retrospective study aimed to illustrate the application value and prospect of the third-generation sequencing technology in lower respiratory tract infection disease.
This study recruited 70 patients with lower respiratory tract infection (LRTI). Pathogen detection of bronchoalveolar lavage fluid (BALF) from all patients was performed using nanopore metagenomic sequencing technology and traditional culture. BALF culture combined with quantitiative PCR (qPCR) was used as a reference standard to analyze the sensitivity and specificity of nanopore sequencing technology. The current study also collected the examination results of enrolled samples using technical methods sputum culture, tuberculosis DNA (TB-DNA), and Xpert MTB/RIF and analyzed the detection efficiency of nanopore sequencing for .
The positive rates of pathogens in 70 BALF samples detected by conventional culture and nanopore sequencing were 25.71% and 84.29%, respectively. Among the 59 positive BALF cases using nanopore sequencing, a total of 31 pathogens were identified, of which the proportions of bacteria, fungi, viruses, and other pathogens were 50%, 17%, 32%, and 1%, respectively. Using the results combined with culture and qPCR detection methods as the standard, the pathogen detection of BALF using nanopore sequencing had a sensitivity of 70% and a specificity of 91.7%. Additionally, the positive rate of the detection of using nanopore sequencing was 33.3% (6/18). The clinical medication plans of 74.3% (52/70) of the patients were referred to the nanopore sequencing results, of which 31 cases changed their treatment strategy, 21 supported the previous treatment plans, and 90% (47/52) of the patients finally had clinical improvement.
BALF detection using nanopore sequencing technology improves the process of detecting pathogens in patients with LRTI, especially for , fungi, and viruses, by reducing the report time from three days to six hours. The clinical application prospect of nanopore sequencing technology is promising in the pathogen diagnosis of LRTI.
在复杂感染或罕见病原体检测中,通常会出现低检出率和不理想的检测结果。本回顾性研究旨在阐述第三代测序技术在下呼吸道感染疾病中的应用价值和前景。
本研究纳入 70 例下呼吸道感染(LRTI)患者。所有患者的支气管肺泡灌洗液(BALF)均采用纳米孔宏基因组测序技术和传统培养进行病原体检测。BALF 培养联合定量 PCR(qPCR)作为参考标准,分析纳米孔测序技术的敏感性和特异性。本研究还收集了纳入样本的技术方法痰培养、结核 DNA(TB-DNA)和 Xpert MTB/RIF 的检查结果,并分析了纳米孔测序对 的检测效率。
传统培养和纳米孔测序分别检测 70 例 BALF 样本中病原体的阳性率为 25.71%和 84.29%。在 59 例经纳米孔测序阳性的 BALF 病例中,共鉴定出 31 种病原体,其中细菌、真菌、病毒和其他病原体的比例分别为 50%、17%、32%和 1%。以联合培养和 qPCR 检测方法的结果为标准,BALF 中病原体的纳米孔测序检测敏感性为 70%,特异性为 91.7%。此外,纳米孔测序检测 的阳性率为 33.3%(6/18)。70 例患者中有 74.3%(52/70)的临床用药方案参考了纳米孔测序结果,其中 31 例改变了治疗策略,21 例支持了之前的治疗方案,90%(47/52)的患者最终临床改善。
纳米孔测序技术检测 BALF 提高了 LRTI 患者病原体检测的过程,特别是减少了报告时间,从三天到六小时,从而提高了检测细菌、真菌和病毒的效率。纳米孔测序技术在 LRTI 病原体诊断中的临床应用前景广阔。